Drugs / AD-SVF

Trials 5

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07230600 Nov 2025 → Dec 2026 expected adhesions of uterus The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Recruiting No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05857358 Jan 2024 → Feb 2026 overdue — Assistance Publique Hopitaux De Marseille Not yet recruiting No outcome recorded
Phase 1/2 NCT02912169 Nov 2015 → Nov 2017 Alzheimer disease Ageless Regenerative Institute Withdrawn No outcome recorded
Phase 1/2 NCT02087397 Mar 2014 → Nov 2017 erectile dysfunction Ageless Regenerative Institute Withdrawn No outcome recorded
Phase not applicable1 trial
— NCT01739504 Mar 2014 → Apr 2017 osteoarthritis Ageless Regenerative Institute Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as AD-SVF ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230600 ↗
4

NCT01739504 ↗

NCT02087397 ↗

NCT05857358 ↗

NCT02912169 ↗

Known as Adipose-Derived Stromal Vascular Fraction “This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction (AD-SVF) implantation performed intra-articularly...” NCT01739504 ↗
2

“The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue.” NCT05857358 ↗

“adipose-derived stromal vascular fraction (AD-SVF) therapy” NCT07230600 ↗

Known as Autologous Adipose-derived Stromal Vascular Fraction “Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal.” NCT02912169 ↗
Modality Cell therapy “Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.” NCT01739504 ↗
Route Other “intra-articular administration of affected joint.” NCT01739504 ↗